A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
Orion Corporation, Orion Pharma
Summary
Multi-site, open-label, first-in-human study with 2 parts (dose escalation and dose expansion) in subjects with selected advanced solid tumours
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Male or female subjects ≥18 years old 2. Subjects must have histological diagnosis of locally advanced (primary or recurrent) or metastatic solid tumour of the kind listed below that is not amenable for treatment with curative intent, e.g.: Part 1: * mesothelioma * epithelioid hemangioendothelioma (EHE) * cholangiocarcinoma (CCA) * head and neck squamous cell carcinoma (HNSCC) * non-small cell lung carcinoma (NSCLC) * colorectal cancer (CRC) * hepatocellular cancer (HCC) * castration-resistant prostate cancer (CRPC) * meningioma * any o…